Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -34.33% is 57% above its 5-year average of -79.38%, near the high end of its 5-year range (-122.09%–-34.33%).
As of the fiscal period ended Tuesday, June 30, 2026. 58.00% above its 12-month average of -81.74%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2027 (2026-06-30): -34.33%.
RETURN ON EQUITY (ROE)
-34.33%
RETURN ON EQUITY (ROE) AVG TTM
-81.74%
RETURN ON EQUITY (ROE) AVG 3Y
-86.36%
RETURN ON EQUITY (ROE) AVG 5Y
-79.38%
RETURN ON EQUITY (ROE) AVG 10Y
-78.94%
RETURN ON EQUITY (ROE) AVG 15Y
-83.25%
RETURN ON EQUITY (ROE) AVG 20Y
-82.85%
CURRENT VS TTM AVG
+58.00%
CURRENT VS 3Y AVG
+60.24%
CURRENT VS 5Y AVG
+56.75%
CURRENT VS 10Y AVG
+56.50%
CURRENT VS 15Y AVG
+58.76%
CURRENT VS 20Y AVG
+58.56%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+18.27%
vs the sector median at left
Sonoma Pharmaceuticals, Inc.
Market Cap
$5.89M
Return on Equity (ROE)
-34.33%
TTM Avg
-81.74%
3Y Avg
-86.36%
5Y Avg
-79.38%
Market Cap
$5.92M
Return on Equity (ROE)
-87.12%
TTM Avg
-90.45%
3Y Avg
-143.11%
5Y Avg
-272.17%
Market Cap
$5.83M
Return on Equity (ROE)
-111.42%
TTM Avg
-84.56%
3Y Avg
-107.54%
5Y Avg
-308.31%
Market Cap
$5.82M
Return on Equity (ROE)
-92.44%
TTM Avg
-28.72%
3Y Avg
10.69%
5Y Avg
23.75%
Market Cap
$5.73M
Return on Equity (ROE)
105.35%
TTM Avg
0.10%
3Y Avg
-37.77%
5Y Avg
-33.57%
Market Cap
$5.70M
Return on Equity (ROE)
-76.07%
TTM Avg
-61.76%
3Y Avg
-59.53%
5Y Avg
-66.20%
Market Cap
$6.11M
Return on Equity (ROE)
-59.21%
TTM Avg
-23.87%
3Y Avg
-948.19%
5Y Avg
-660.49%
Market Cap
$5.63M
Return on Equity (ROE)
-92.08%
TTM Avg
-1221.97%
3Y Avg
-730.41%
5Y Avg
-532.44%
Market Cap
$6.28M
Return on Equity (ROE)
-304.78%
TTM Avg
-566.96%
3Y Avg
-321.57%
5Y Avg
-251.82%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | $5.89M | -34.33% | -81.74% | -86.36% | -79.38% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.92M | -87.12% | -90.45% | -143.11% | -272.17% |
| Lucyd, Inc (LUCY)vs › | $5.83M | -111.42% | -84.56% | -107.54% | -308.31% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.82M | -92.44% | -28.72% | 10.69% | 23.75% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.73M | 105.35% | 0.10% | -37.77% | -33.57% |
| enVVeno Medical Corporation (NVNO)vs › | $5.70M | -76.07% | -61.76% | -59.53% | -66.20% |
| Scienture Holdings, Inc. (SCNX)vs › | $6.11M | -59.21% | -23.87% | -948.19% | -660.49% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | -92.08% | -1221.97% | -730.41% | -532.44% |
| Femasys Inc. (FEMY)vs › | $6.28M | -304.78% | -566.96% | -321.57% | -251.82% |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | -163.18% | -235.11% | -195.15% | -161.13% |
ROE
-34.3%
ROA
-12.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -34.33% |
| 2026-03-31 | -102.58% |
| 2025-12-31 | -98.19% |
| 2025-09-30 | -91.87% |
| 2025-03-31 | -78.37% |
| 2024-12-31 | -76.96% |
| 2024-09-30 | -68.87% |
| 2024-06-30 | -91.66% |
| 2024-03-31 | -78.78% |
| 2023-12-31 | -75.85% |
| 2023-09-30 | -108.35% |
| 2023-06-30 | -78.46% |
| 2023-03-31 | -64.57% |
| 2022-12-31 | -122.09% |
| 2022-09-30 | -82.50% |
| 2022-06-30 | -61.25% |
| 2022-03-31 | -58.48% |
| 2021-12-31 | -51.95% |
| 2021-09-30 | -48.06% |
| 2021-06-30 | -114.43% |
| 2021-03-31 | -88.48% |
| 2020-12-31 | -22.91% |
| 2020-09-30 | -28.15% |
| 2020-06-30 | -40.12% |
| 2020-03-31 | -58.82% |
| 2019-12-31 | -42.77% |
| 2019-09-30 | -58.49% |
| 2019-06-30 | -66.28% |
| 2019-03-31 | -112.48% |
| 2018-12-31 | -99.99% |
| 2018-09-30 | -131.92% |
| 2018-06-30 | -113.06% |
| 2018-03-31 | -93.49% |
| 2017-12-31 | -84.18% |
| 2017-09-30 | 45.88% |
| 2017-06-30 | 44.80% |
| 2017-03-31 | 43.28% |
| 2016-12-31 | 38.49% |
| 2016-09-30 | -175.13% |
| 2016-06-30 | -134.06% |
| 2016-03-31 | -100.22% |
| 2015-12-31 | -96.00% |
| 2015-09-30 | -107.16% |
| 2015-06-30 | -94.04% |
| 2015-03-31 | -68.05% |
| 2014-12-31 | 9.64% |
| 2014-09-30 | 45.31% |
| 2014-06-30 | 40.11% |
| 2014-03-31 | 30.96% |
| 2013-12-31 | -181.54% |
| 2013-09-30 | -481.81% |
| 2013-06-30 | -289.95% |
| 2013-03-31 | -133.08% |
| 2012-12-31 | -151.98% |
| 2011-03-31 | -467.25% |
| 2010-12-31 | -283.41% |
| 2010-09-30 | -150.03% |
| 2010-06-30 | -127.43% |
| 2010-03-31 | -116.85% |
| 2009-12-31 | -161.84% |
| 2009-09-30 | -177.40% |
| 2009-03-31 | -778.14% |
| 2008-09-30 | -431.33% |
| 2008-06-30 | -191.08% |
| 2008-03-31 | -131.83% |
| 2007-12-31 | -267.54% |
| 2007-09-30 | -161.79% |
| 2007-06-30 | -213.64% |
| 2007-03-31 | -133.01% |
| 2006-03-31 | -314.79% |
| 2005-03-31 | -750.73% |
